It acts by targeting FMS-like tyrosine kinase 3 (FLT3), spleen tyrosine kinase (SYK), Janus Kinase 1 and 2 (JAK1/2), tyrosine protein kinase c KIT, ribosomal protein S6 kinase (RSK2), ...

Gynecology Department, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250002, China Department of Oncology, Qingdao Municipal Hospital, ...

(A) Increased expression of TAK1 in ECA-109 cells transfected with a plasmid expressing Map3k7. (B) Increased expression of TAK1 inhibits the morphological changes to form spindle-shaped mesenchymal ...

aDouglas Mental Health University Institute, Department of Psychiatry, McGill University, Montréal, H4H 1R3, Canada bLudmer Centre for Neuroinformatics and Mental Health, McGill University, Montréal, ...

They further identify SF3B1K700E-induced missplicing of Map3k7 as a critical mechanism that enables isolated pancreas cancer cells to survive TGFβ-induced EMT, senescence and cell death. Together with ...

A total of 30 BC tissues, 30 corresponding noncancerous tissues, and 10 normal control (NC) breast tissues were obtained to detect the levels of miR-143, extracellular signal-regulated kinase 5 (ERK5) ...

Researchers from Eydis Bio Inc. reported the discovery and preclinical characterization of a novel mitogen-activated protein kinase kinase kinase 7 (MAP3K7/TAK1) inhibitor, EYD-001, being developed ...

The preclinical Alnitak program is developing an oral medication that specifically binds to and inhibits the TAK1 (MAP3K7) target protein, which has been shown to serve as a master regulator of ...

A robust proteomics strategy is used to elucidate the time‐resolved interplay of protein‐protein interactions (PPIs) and post‐translational modifications (PTMs) in human immune cells with a focus on ...

In addition, we define a role of MAP3K7 and a MAP3K7-p38 MAPK axis in human terminal erythroid differentiation and created a SF3B1 cell model that recapitulates many of the terminal erythroid ...